×
Don't Miss Out!
Get your weekly Breakfast Briefing eNewsletter, filled with news, trends, and vital information from DIA!
Back to Agenda
Beyond Weight Loss: Pioneering the Future of Obesity Drug Development
Session Chair(s)
Jingyu (Julia) Luan, PhD
Executive Regulatory Science Director, BioPharmaceuticals R&D
AstraZeneca, United States
This forum on obesity drug development helps the audience understand the present landscape, participate in discussions on the prevention and treatment of comorbidities, and assess various strategies in enhancing clinical trial efficiency.
Learning Objective : Understand the present landscape, opportunities, and challenges of obesity drug development; Delve into discussions on the prevention and treatment of comorbidities associated with obesity; Assess various considerations and strategies in enhancing the efficiency of obesity drug development.
Speaker(s)
Panelist
Maria Vassileva, PhD
DIA, United States
Chief Science and Regulatory Officer
Panelist
Representative Invited
FDA, United States
Panelist
Brad Jordan, PhD
Eli Lilly and Company, United States
Associate Vice President, Regulatory Policy and Strategy
Have an account?